

Access this article on [ScienceDirect](#)

A provider global assessment quality measure for clinical practice for inflammatory skin disorders

[Alice Gottlieb](#), MD, PhD^{a,*}, [Nicole Salame](#), BA^b, [April W. Armstrong](#), MD, MPH^c, [Joseph F. Merola](#), MD, MMSc^d, [Sylvia Parra](#), MD^e, [Junko Takeshita](#), MD, PhD, MSCE^f, [Suephy C. Chen](#), MD, MS^g, [John Latella](#), BS, MS^h, [Marta Van Beek](#), MD, MPHⁱ on behalf of International Dermatology Outcome Measures and the American Academy of Dermatology

PlumX Metrics

DOI: <https://doi.org/10.1016/j.jaad.2018.09.017> | Check for updates

Article Info

[Abstract](#) | [Full Text](#) | [Images](#) | [References](#)

In our evolving health care system, dermatologists are increasingly being asked to prove the value of care they provide to patients with severe skin diseases. Current quality measures for inflammatory dermatoses have limited validity and feasibility. Through collaboration and a modified Delphi process, International Dermatology Outcome Measures and the American Academy of Dermatology sought to reach consensus on a valid and feasible provider-assessed global disease severity metric to be incorporated into a quality measure for inflammatory dermatoses. To inform the modified Delphi process, a review of the literature was performed, and data were collected on current provider-assessed global disease severity metrics. After literature review, 36 members of International Dermatology Outcome Measures and the American Academy of Dermatology participated in the modified Delphi process to reach consensus on features of the metric. Psoriasis, atopic dermatitis, and acne achieved overwhelming consensus for inflammatory dermatoses that could be measured in a global disease severity metric. Consensus was also reached on the use of a 5-point ordinal scale with descriptors provided through referenced electronic platforms. Expert development of quality measures incorporating this metric and its inclusion in data collection platforms are critical to enabling dermatologists to prove the value of care provided to patients with severe inflammatory dermatoses.

Key words:
[acne](#), [atopic dermatitis](#), [IDEOM](#), [inflammatory dermatoses](#), [quality of care](#), [quality measure](#), [psoriasis](#)

To access this article, please choose from the options below

Society Member Login

Society Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features

OR

Purchase access to this article

- [\\$35.95 USD | PDF Download and 24 Hours Online Access](#)

Claim Access

If you are a current subscriber with Society Membership or an Account Number, [claim your access now](#).

Subscribe to this title

[Purchase a subscription](#) to gain access to this and all other articles in this journal.

Article Tools

- [PDF \(596 KB\)](#)
- [Download Images\(.ppt\)](#)
- [About Images & Usage](#)

- [Email Article](#)
- [Add to My Reading List](#)
- [Export Citation](#)
- [Create Citation Alert](#)
- [Cited by in Scopus \(0\)](#)

- [Request Permissions](#)
- [Order Reprints](#)
(100 minimum order)

Related Articles

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Journal of the American Academy of Dermatology, Vol. 80, Issue 4

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Journal of the American Academy of Dermatology, Vol. 80, Issue 4

The burden of skin disease in the United States

Journal of the American Academy of Dermatology, Vol. 76, Issue 5

Eosinophilic dermatosis of hematologic malignancy: A